福安药业：2025年业绩有下降

Core Viewpoint - The company acknowledges the significant lag of its stock price compared to the market and attributes this to various factors including macroeconomic conditions, industry policies, and market sentiment [2] Group 1: Company Response - The company expresses gratitude for investor support and addresses concerns regarding stock price performance [2] - The company indicates that it has not considered share buybacks due to the influence of industry policies on its performance, particularly noting a projected decline in 2025 [2] - The company commits to optimizing management and operations to enhance corporate value and shareholder returns in the future [2]